Altered antibodies

• US 6,982,321 B2
• Filed: 01/24/2003
• Issued: 01/03/2006
• Est. Priority Date: 03/27/1986
• Status: Expired due to Fees

• Current Assignee: BTG International Limited (Boston Scientific Corporation)
• Original Assignee: BTG International Limited (Boston Scientific Corporation), Medical Research Council (Government of United Kingdom)
• Inventors: Winter, Gregory Paul
• Primary Examiner(s): HELMS, LARRY RONALD
• Application Number:
  US10/351,748
• Publication Number:
  US 20040127688A1
• Time in Patent Office: 1,075 Days
• Field of Search: 530/387.1, 530/387.3, 424/130.1
• US Class Current: 530/387.3
• CPC Class Codes: C07K 16/464 Igs containing CDR-residues from one specie grafted between FR-residues from another
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

An altered antibody is produced by replacing the complementarity determining regions (CDRs) of a variable region of an immunoglobulin (Ig) with the CDRs from an Ig of different specificity, using recombinant DNA techniques. The gene coding sequence for producing the altered antibody may be produced by site-directed mutagenesis using long oligonucleotides or using gene synthesis.

Claims

1. An antibody comprising a human kappa light chain variable domain, wherein said light chain variable domain comprises a set of tour human Kabat framework regions (FRs), wherein each of said FRs in said set of four FRs comprises residues identical to the most common residue in each position in a Kabat alignment of a human kappa sub-group 1, and wherein said antibody binds an antigen.

2. An antibody comprising a human kappa light chain variable domain, said light chain variable domain comprising a set of four human Kabat framework regions (FRs), wherein said antibody incorporates FRs comprising residues identical to the most common residue in each position in a Kabat alignment of a human kappa sub-group 1, and wherein said antibody has three Kabat complementarity determining regions (CDRs) comprising sequences of amino acid residues, wherein said sequences are not human, and wherein said antibody binds the same antigen as a non-human antibody having a kappa light chain comprising said sequences.

4. The antibody of claim 2 or 3, wherein said antibody incorporates a human framework region (FR1) comprising amino acids 20–

42 of SEQ. ID NO;

37.

5. The antibody of claim 2 or 3, wherein said antibody incorporates a human framework region (FR2) comprising amino acids 54–

68 of SEQ. ID NO;

37.

6. The antibody of claim 2 or 3, wherein said antibody incorporates a human framework region (FR4) comprising amino acids 117–

127 of SEQ. ID NO;

37.

7. The antibody of claim 2 or 3, wherein said non-human antibody is a rodent antibody.

8. The antibody of claim 7, wherein said rodent antibody is a mouse antibody.

9. The antibody of claim 2 or 3, wherein each of said FRs in said set of four FRs comprises residues identical to the most common residue in each position in the Kabat alignment of the human kappa sub-group 1.

10. The antibody of claim 2 or 3, wherein three said set of four human Kabat FRs comprise residues identical to the most common residue in each position in the Kabat alignment of the human kappa sub-group 1, and wherein one of said set of four FRs contains at least one replacement amino acid residues.

11. The antibody of claim 2 or 3, wherein three of said set of four human Kabat FRs comprise residues identical to the most common residue in each position in the Kabat alignment of the human kappa sub-group 1, and wherein one of said set of four FRs contains at least two replacement amino acid residues.

12. The antibody of claim 2 or 3, wherein said antibody further comprises a heavy chain variable domain, said heavy chain variable domain comprising a set of four heavy chain human Kabat framework regions (FRs) and three heavy chain Kabat CDRs comprising amino acid residues from a donor antibody.

13. The antibody of claim 12, wherein said set of four heavy chain human Kabat FRs comprises an alteration in an acceptor FR of at least one replacement of a first amino acid residue with a second amino acid residue from a corresponding position in a donor FR of the donor antibody, and wherein a 200% van der Waals surface thrown around said second amino acid residue identifies a packing interaction with one or more amino acid residues in a CDR in the donor antibody.

14. The antibody of claim 13, wherein the packing interaction enhances the antigen-binding activity of the antibody compared to a second antibody, wherein the second antibody lacks the alteration in the acceptor FR, but is otherwise identical to the antibody comprising said alteration.

15. The antibody according to claim 12, wherein said antibody is an IgG isotype.

16. The antibody according to claim 12, wherein said antibody is selected from the group consisting of an IgG1, IgG2 and IgG4 isotype.

17. The antibody according to claim 12, wherein said antibody is an IgG1 antibody, and wherein said IgG1 antibody is lytic.

18. The antibody according to claim 12, wherein said antibody is a therapeutic antibody.

19. The antibody according to claim 12, wherein said antibody has effector functions.

20. The antibody according to claim 19, wherein said effector function is complement activation.

21. The antibody according to claim 19, wherein said effector function is antibody-dependent cell-mediated cytotoxicity (ADCC).

3. An antibody comprising a human kappa light chain variable domain, said light chain variable domain comprising a set of four human Kabat framework regions (FRs), wherein said antibody incorporates FRs comprising residues identical to the most common residue in each position in a Kabat alignment of a human kappa sub-group 1, wherein said antibody has three Kabat complementarity determining regions (CDRs) comprising amino acid residues from a non-human antibody, and wherein said antibody binds the same antigen as the non-human antibody.

22. An antibody comprising a human kappa light chain variable domain having a set of four framework regions (FRs) of a human antibody and three complementarity determining regions (CDRs) comprising residues from a non-human antibody, wherein said antibody binds the same antigen as the non-human antibody.

23. The antibody of claim 22, wherein said non-human antibody is a mouse antibody.

24. The antibody of claim 22, wherein said non-human antibody is a rodent antibody.